Brain changes evident in scans before memory, cognitive decline
In 2012, Andrew and Barbara Taylor and the Crawford Taylor Foundation pledged $20 million to the Department of Psychiatry at Washington University’s School of Medicine to establish a research institute dedicated to advancing new treatments for mental illnesses. Just six years later, investigators in the department’s Taylor Family Institute for Innovative Psychiatric Research are on […]
A $10 million commitment from Andrew Taylor, a life trustee at Washington University in St. Louis, and his wife, Barbara, will establish the Taylor Family Scholarship Challenge, which will match all new and increased gifts for undergraduate scholarships received by the conclusion of Leading Together: The Campaign for Washington University on June 30, 2018, as well as […]
Grant to renew annual clinic, advance understanding of rare disorder
Parent-child interactive therapy decreases depressive symptoms in kids.
A national study led by institute affiliate Charles Conway, MD, indicates that people treated with nerve stimulation experience significant improvements in quality of life, even when their depression symptoms don’t completely dissipate.
In the new research, Steve Mennerick, Institute scientific director, and his colleagues focused on GABA receptors located on neurons in the brain’s hippocampus, a part of the brain involved in learning and memory. Using CRISPR, they mutated the delta-type GABA receptors to isolate and test their role in brain functioning.
Theodore J. Cicero, PhD, the John P. Feighner Professor of Psychiatry at Washington University School of Medicine in St. Louis, is the 2018 recipient of the Pioneer Award from the National Council on Alcoholism and Drug Abuse (NCADA).
We are so excited to have Meaghan Creed and Lex Kravitz headed to St. Louis to join the Washington University School of Medicine research community.
Nitrous oxide, or laughing gas, has shown early promise as a potential treatment for severe depression in patients whose symptoms don’t respond to standard therapies. The pilot study was believed to be the first research in which patients with depression were given laughing gas.